Literature DB >> 24900791

Replacement of the Disulfide Bridge in a KLK3-Stimulating Peptide Using Orthogonally Protected Building Blocks.

Kristian Meinander1, Miikka Pakkala2, Janne Weisell2, Ulf-Håkan Stenman3, Hannu Koistinen3, Ale Närvänen2, Erik A A Wallén1.   

Abstract

Peptide "B-2", which is one of the most potent kallikrein-related peptidase 3 (KLK3)-stimulating compounds, consists of 12 amino acids and is cyclized by a disulfide bridge between the N- and C-terminal cysteines. Orthogonally protected building blocks were used in the peptide synthesis to introduce a disulfide bridge mimetic consisting of four carbon atoms. The resulting pseudopeptides with alkane and E-alkene linkers doubled the proteolytic activity of KLK3 at a concentration of 14 μM. They were almost as potent as the parent "B-2" peptide, which gives a 3.6-fold increase in the proteolytic activity of KLK3 at the same concentration.

Entities:  

Keywords:  Disulfide bridge mimetic; human kallikrein-related peptidase 3; peptide synthesis; prostate specific antigen; proteolytic activity; pseudopeptide

Year:  2013        PMID: 24900791      PMCID: PMC4027621          DOI: 10.1021/ml400419g

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  17 in total

1.  Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer.

Authors:  I Papadopoulos; E Sivridis; A Giatromanolaki; M I Koukourakis
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

2.  Peptides binding to prostate-specific antigen enhance its antiangiogenic activity.

Authors:  Johanna M Mattsson; Ale Närvänen; Ulf-Håkan Stenman; Hannu Koistinen
Journal:  Prostate       Date:  2012-03-16       Impact factor: 4.104

3.  Synthesis of orthogonally protected disulfide bridge mimetics.

Authors:  Andrew C Tadd; Kristian Meinander; Kristina Luthman; Erik A A Wallén
Journal:  J Org Chem       Date:  2010-12-22       Impact factor: 4.354

4.  Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.

Authors:  Annukka Paju; Kristina Hotakainen; Yue Cao; Timo Laurila; Virgil Gadaleanu; Akseli Hemminki; Ulf-Håkan Stenman; Anders Bjartell
Journal:  Eur Urol       Date:  2007-02-05       Impact factor: 20.096

5.  Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity.

Authors:  P Wu; J Leinonen; E Koivunen; H Lankinen; U H Stenman
Journal:  Eur J Biochem       Date:  2000-10

6.  Antiangiogenic activity of prostate-specific antigen.

Authors:  A H Fortier; B J Nelson; D K Grella; J W Holaday
Journal:  J Natl Cancer Inst       Date:  1999-10-06       Impact factor: 13.506

7.  Mimetics of the disulfide bridge between the N- and C-terminal cysteines of the KLK3-stimulating peptide B-2.

Authors:  Miikka Pakkala; Janne Weisell; Can Hekim; Jouko Vepsäläinen; Erik A A Wallen; Ulf-Håkan Stenman; Hannu Koistinen; Ale Närvänen
Journal:  Amino Acids       Date:  2009-12-05       Impact factor: 3.520

Review 8.  Development of peptides specifically modulating the activity of KLK2 and KLK3.

Authors:  Hannu Koistinen; Ale Närvänen; Miikka Pakkala; Can Hekim; Johanna M Mattsson; Lei Zhu; Pirjo Laakkonen; Ulf-Håkan Stenman
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

Review 9.  Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

Authors:  Hans Lilja; David Ulmert; Andrew J Vickers
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

10.  Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.

Authors:  Ping Wu; Ulf-Håkan Stenman; Miikka Pakkala; Ale Närvänen; Jari Leinonen
Journal:  Prostate       Date:  2004-03-01       Impact factor: 4.104

View more
  2 in total

1.  Targeting cancer-specific glycans by cyclic peptide lectinomimics.

Authors:  Maria C Rodriguez; Austin B Yongye; Mihael Cudic; Karina Martinez Mayorga; Enbo Liu; Barbara M Mueller; Jon Ainsley; Tatyana Karabencheva-Christova; Christo Z Christov; Mare Cudic; Predrag Cudic
Journal:  Amino Acids       Date:  2017-09-11       Impact factor: 3.520

2.  KLK-targeted Therapies for Prostate Cancer.

Authors:  Koistinen Hannu; Mattsson Johanna; Stenman Ulf-Håkan
Journal:  EJIFCC       Date:  2014-09-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.